var data={"title":"Treatment of latent tuberculosis infection in HIV-infected adults","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Treatment of latent tuberculosis infection in HIV-infected adults</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/contributors\" class=\"contributor contributor_credentials\">Dick Menzies, MD, MSc</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/contributors\" class=\"contributor contributor_credentials\">C Fordham von Reyn, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 15, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H107991584\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Human immunodeficiency virus (HIV) infection has had a profound impact on the epidemiology, clinical manifestations, and outcome of tuberculosis (TB) [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/1,2\" class=\"abstract_t\">1,2</a>]. The intersection of these two epidemics has been associated with a major surge in TB cases, particularly in resource-limited settings [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/3\" class=\"abstract_t\">3</a>]. The World Health Organization (WHO) estimates that 13 percent of deaths among patients with acquired immune deficiency syndrome (AIDS) worldwide are related to TB [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/4\" class=\"abstract_t\">4</a>]. The impact of HIV on TB disease is particularly notable in sub-Saharan Africa, where the incidence of TB increased between 1990 to 2005 from approximately 150 to over 400 per 100,000 population [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/1,3\" class=\"abstract_t\">1,3</a>].</p><p>Issues related to prevention of active TB disease through treatment of latent tuberculosis infection (LTBI) in the HIV-infected patient will be reviewed here. The diagnosis of LTBI in the HIV-infected patient and treatment of active TB disease are discussed separately. (See <a href=\"topic.htm?path=treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy\" class=\"medical medical_review\">&quot;Treatment of pulmonary tuberculosis in HIV-infected adults: Initiation of therapy&quot;</a> and <a href=\"topic.htm?path=approach-to-diagnosis-of-latent-tuberculosis-infection-tuberculosis-screening-in-adults\" class=\"medical medical_review\">&quot;Approach to diagnosis of latent tuberculosis infection (tuberculosis screening) in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H8400290\"><span class=\"h1\">GENERAL CONCEPTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Tuberculosis (TB) infection is caused by inhalation of viable tuberculous bacilli; these organisms usually persist in an inactive state, known as latent TB infection (LTBI); in some cases following inhalation, there is rapid progression to active TB disease. Individuals with LTBI are asymptomatic and not infectious. Latent TB bacilli remain viable and may reactivate years later, causing active symptomatic and transmissible TB disease [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/5\" class=\"abstract_t\">5</a>].</p><p>The natural history of tuberculosis is discussed further separately. (See <a href=\"topic.htm?path=tuberculosis-natural-history-microbiology-and-pathogenesis\" class=\"medical medical_review\">&quot;Tuberculosis: Natural history, microbiology, and pathogenesis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H670608\"><span class=\"h2\">Risk factors for progression</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Risk factors for progression to active TB disease include [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/6-9\" class=\"abstract_t\">6-9</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Abnormal chest radiograph (eg, fibrotic lesion)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Contact with an active TB case</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A positive skin test for LTBI</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Origin from a country with high TB incidence rates</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Detectable HIV RNA</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Low CD4 cell count (eg, &lt;200 <span class=\"nowrap\">cells/mm<sup>3</sup>)</span></p><p/><p>Following primary TB infection, HIV-infected patients are at greater risk of progressing to active TB disease than HIV-uninfected individuals [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/10,11\" class=\"abstract_t\">10,11</a>]; the interval between exposure and disease can be less than two months [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/11,12\" class=\"abstract_t\">11,12</a>]. In addition, HIV-infected patients with LTBI are 30 to 100 times more likely to reactivate with TB disease than HIV-uninfected individuals [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/13-16\" class=\"abstract_t\">13-16</a>].</p><p>Antiretroviral therapy reduces risk of developing active TB disease among individuals with HIV and LTBI [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/6,7,17,18\" class=\"abstract_t\">6,7,17,18</a>]. (See <a href=\"#H1417217608\" class=\"local\">'Initiation of antiretroviral therapy'</a> below.)</p><p class=\"headingAnchor\" id=\"H8400317\"><span class=\"h2\">Rationale for LTBI treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of latent TB is associated with two important benefits: (1) reduction in the likelihood of progression to active TB disease, and (2) reduction in TB transmission.</p><p>Treatment of LTBI reduces the risk of progression to active TB disease, reducing TB-related morbidity and mortality [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/1,19,20\" class=\"abstract_t\">1,19,20</a>]. Among patients in Africa with HIV and LTBI, the risk of developing active TB disease is 5 to 10 percent per year [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/4,21,22\" class=\"abstract_t\">4,21,22</a>]. Overall, treatment of LTBI in individuals with HIV infection reduces active TB disease by 62 percent and mortality by 26 percent; most studies have demonstrated the benefit is greatest among those with positive test for LTBI (<a href=\"topic.htm?path=tuberculin-skin-test-drug-information\" class=\"drug drug_general\">tuberculin skin test</a> or interferon-gamma release assay) [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/21\" class=\"abstract_t\">21</a>].</p><p>Treatment of LTBI also reduces TB transmission [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/6,21,23\" class=\"abstract_t\">6,21,23</a>]. Mathematical models have predicted that provision of LTBI therapy to at least half of individuals with HIV and LTBI would be cost-effective and would result in a substantial reduction in TB disease [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/23,24\" class=\"abstract_t\">23,24</a>].</p><p>For these reasons, treatment of LTBI in HIV-infected persons has been strongly recommended for many years by expert panels [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/25,26\" class=\"abstract_t\">25,26</a>]. However, despite consistent and clear recommendations from authoritative agencies, including the World Health Organization [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/4,27\" class=\"abstract_t\">4,27</a>], it is estimated that only 1.3 percent of all HIV-infected patients with LTBI worldwide receive treatment [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/28\" class=\"abstract_t\">28</a>].</p><p class=\"headingAnchor\" id=\"H7701782\"><span class=\"h1\">CLINICAL APPROACH</span></p><p class=\"headingAnchor\" id=\"H291024591\"><span class=\"h2\">Treatment of LTBI</span></p><p class=\"headingAnchor\" id=\"H7701804\"><span class=\"h3\">Whom to treat</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Latent tuberculosis infection (LTBI) treatment is warranted for HIV-infected patients in the following circumstances [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/1\" class=\"abstract_t\">1</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Individuals with recent contact with a person with active tuberculosis (TB) disease</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Individuals with a history of inadequately treated healed TB (eg, fibrotic disease on chest radiograph), regardless of test results for LTBI (see <a href=\"#H670608\" class=\"local\">'Risk factors for progression'</a> above)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Individuals with evidence of LTBI by <a href=\"topic.htm?path=tuberculin-skin-test-drug-information\" class=\"drug drug_general\">tuberculin skin test</a> (TST) or interferon-gamma release assay (IGRA)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Individuals living in resource-limited areas of high TB incidence where testing for LTBI is not available</p><p/><p>In 2011, the World Health Organization (WHO) recommended testing for LTBI prior to initiation of therapy but also indicated this should not be an absolute requirement among HIV-infected patients living in areas of high TB incidence [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/4\" class=\"abstract_t\">4</a>]. In resource-limited settings where LTBI testing is not available, LTBI treatment is warranted for all HIV-infected patients. Several studies have demonstrated that the benefits of LTBI treatment are greatest among HIV-infected patients with evidence of LTBI by TST or IGRA [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/1,6,7,21,29-31\" class=\"abstract_t\">1,6,7,21,29-31</a>].</p><p>The benefit of LTBI treatment was not restricted to patients with evidence of LTBI in a South African trial published in 2014; the authors concluded that LTBI treatment should be administered to all patients receiving antiretroviral therapy (ART) in areas with moderate or high incidence of TB (irrespective of TST or IGRA status) [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/32\" class=\"abstract_t\">32</a>]. However, limitations of the study included incomplete assessment for latent and active TB and prior treatment for active TB among a substantial proportion of patients.</p><p>Issued related to diagnosis of LTBI are discussed further separately. (See <a href=\"topic.htm?path=approach-to-diagnosis-of-latent-tuberculosis-infection-tuberculosis-screening-in-adults\" class=\"medical medical_review\">&quot;Approach to diagnosis of latent tuberculosis infection (tuberculosis screening) in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H7704706\"><span class=\"h3\">Prior to treatment</span></p><p class=\"headingAnchor\" id=\"H7704536\"><span class=\"h4\">Assessment for TB disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Prior to initiation of treatment for LTBI, all patients must be evaluated for active TB disease to avoid monotherapy and the risk of TB drug resistance [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/33\" class=\"abstract_t\">33</a>]. (See <a href=\"topic.htm?path=approach-to-diagnosis-of-latent-tuberculosis-infection-tuberculosis-screening-in-adults\" class=\"medical medical_review\">&quot;Approach to diagnosis of latent tuberculosis infection (tuberculosis screening) in adults&quot;</a>.)</p><p>The increased risk of active TB begins as soon as HIV infection is acquired and is especially high among patients with a CD4 cell count &lt;200 <span class=\"nowrap\">cells/mm<sup>3</sup></span> [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/34\" class=\"abstract_t\">34</a>]. Patients with advanced immunosuppression may present with atypical clinical manifestations including extrapulmonary TB disease <span class=\"nowrap\">and/or</span> mediastinal lymphadenopathy or with subclinical infection and a normal chest radiograph. The diagnosis of active TB disease is discussed in detail separately. (See <a href=\"topic.htm?path=diagnosis-of-pulmonary-tuberculosis-in-adults\" class=\"medical medical_review\">&quot;Diagnosis of pulmonary tuberculosis in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H7704620\"><span class=\"h4\">Baseline laboratory testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The optimal approach to baseline assessment of aminotransferases for HIV-infected patients receiving treatment for LTBI (in the absence of other risk factors) is uncertain; some favor baseline laboratory testing, particularly for patients receiving antiretroviral therapy [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/35\" class=\"abstract_t\">35</a>]. In earlier guidelines, HIV infection was considered a risk factor for drug-induced liver injury [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/25\" class=\"abstract_t\">25</a>]. Subsequently, an extensive review concluded that the likelihood of developing <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> (INH)-related hepatotoxicity among HIV-infected individuals is comparable with that of HIV-uninfected individuals [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/36\" class=\"abstract_t\">36</a>]; no direct comparisons through clinical trials have been performed.</p><p>Baseline laboratory testing is warranted for individuals with risk for hepatotoxicity (eg, alcoholic hepatitis, viral hepatitis) [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/25,37\" class=\"abstract_t\">25,37</a>]. Some experts suggest withholding <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> in patients with symptomatic hepatitis with an alanine aminotransferase level (ALT) greater than three times the upper limit of normal and among those with an ALT greater than five times the upper limit of normal, regardless of the presence or absence of symptomatic hepatitis [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/25,36\" class=\"abstract_t\">25,36</a>]. Issues related to clinical monitoring for patients on INH are discussed further separately. (See <a href=\"#H7712614\" class=\"local\">'Patient monitoring'</a> below and <a href=\"topic.htm?path=isoniazid-an-overview\" class=\"medical medical_review\">&quot;Isoniazid: An overview&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H7701941\"><span class=\"h3\">Treatment regimens</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The approach to treatment of LTBI varies by geographic location; the difference is largely related to the likelihood of recurrent TB exposure and reinfection.</p><p class=\"headingAnchor\" id=\"H7701972\"><span class=\"h4\">Low-incidence settings</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Regimens for treatment of LTBI in HIV-infected individuals in low-incidence settings (TB incidence rate &lt;100 per 100,000 population) should be selected based on the individual's ART regimen, as discussed below. In the United States, the Centers for Disease Control and Prevention recommends one of three regimens for LTBI treatment [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/38\" class=\"abstract_t\">38</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">Isoniazid</a> daily or twice weekly for 9 months</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">Isoniazid</a> plus <a href=\"topic.htm?path=rifapentine-drug-information\" class=\"drug drug_general\">rifapentine</a> once weekly for 12 weeks</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">Rifampin</a> (or <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a>) daily for 4 months</p><p/><p>INH monotherapy is the preferred agent for treatment of LTBI because of its favorable toxicity profile and treatment completion rates [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/4,7,18,21,39-43\" class=\"abstract_t\">4,7,18,21,39-43</a>]. A duration of nine months of INH has been recommended for HIV-infected patients in resource-rich settings by various experts, based on inference from clinical trials in HIV-uninfected patients and subgroup analyses of data from trials using treatment interventions of different durations [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/1,25,26,42\" class=\"abstract_t\">1,25,26,42</a>]. Data are limited for six months of INH; the efficacy is less, but completion rates are better, so overall effectiveness is similar to nine months INH [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/25,26\" class=\"abstract_t\">25,26</a>]. <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">Isoniazid</a> should be supplemented with pyridoxine at a dose of 25 <span class=\"nowrap\">mg/day</span> to prevent peripheral neuropathy [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/44\" class=\"abstract_t\">44</a>].</p><p><a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">Isoniazid</a> plus <a href=\"topic.htm?path=rifapentine-drug-information\" class=\"drug drug_general\">rifapentine</a> (given as directly observed therapy once weekly for 12 weeks) is an attractive alternative to 9 months of INH, given the shorter duration and lower risk of hepatotoxicity yet equivalent efficacy [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/45\" class=\"abstract_t\">45</a>]. This regimen may be used for otherwise healthy HIV-infected patients with LTBI who are not on ART [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/45-47\" class=\"abstract_t\">45-47</a>]. In addition, efavirenz- or raltegravir-based regimens (in combination with either <a href=\"topic.htm?path=abacavir-and-lamivudine-drug-information\" class=\"drug drug_general\">abacavir-lamivudine</a> or <a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-and-emtricitabine-drug-information\" class=\"drug drug_general\">tenofovir disoproxil fumarate-emtricitabine</a> <span class=\"nowrap\">[TDF/FTC])</span> can be used safely with once-weekly isoniazid plus rifapentine [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/48-50\" class=\"abstract_t\">48-50</a>]. Further data on potential drug-drug interactions for patients on antiretroviral therapy are needed; rifapentine induces cytochrome P450 isoenzymes and so can potentially cause significant interactions [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/47\" class=\"abstract_t\">47</a>]. In one study, <a href=\"topic.htm?path=raltegravir-drug-information\" class=\"drug drug_general\">raltegravir</a> concentrations were modestly increased when given with once-weekly rifapentine, suggesting that this regimen can be used with <a href=\"topic.htm?path=efavirenz-drug-information\" class=\"drug drug_general\">efavirenz</a> or raltegravir without dose adjustment [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/37\" class=\"abstract_t\">37</a>]. In another study, combined use of <a href=\"topic.htm?path=dolutegravir-drug-information\" class=\"drug drug_general\">dolutegravir</a> with once-weekly isoniazid-rifapentine in healthy HIV-uninfected volunteers resulted in elevated transaminases and a flu-like syndrome in two out of four subjects, accompanied by endogenous cytokine release [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/51\" class=\"abstract_t\">51</a>]. This small pharmacokinetics study (which was stopped early when these adverse events occurred) raises concerns about combined use of these drugs. Until further information is available regarding this unusual but potentially serious interaction, once-weekly isoniazid-rifapentine should not be given to HIV-infected patients receiving dolutegravir.</p><p><a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">Rifampin</a> or <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> for four months may be considered for treatment of LTBI in HIV-infected individuals, but clinicians should pay careful attention to potential drug-drug interactions with specific antiretroviral medications [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/50\" class=\"abstract_t\">50</a>], particularly protease inhibitors or nonnucleoside reverse transcriptase inhibitors (NNRTIs) [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/29,52\" class=\"abstract_t\">29,52</a>]. Furthermore, there are no data on the use of rifampin or rifabutin as monotherapy for prevention of active TB disease in HIV-infected patients. (See <a href=\"topic.htm?path=treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy#H11\" class=\"medical medical_review\">&quot;Treatment of pulmonary tuberculosis in HIV-infected adults: Initiation of therapy&quot;, section on 'Drug interactions'</a>.)</p><p><a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">Rifampin</a> plus <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a> should not be used for treatment of LTBI due to hepatotoxicity [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/44,53\" class=\"abstract_t\">44,53</a>].</p><p class=\"headingAnchor\" id=\"H3662714639\"><span class=\"h4\">High-incidence settings</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In settings with high rates of TB incidence (&ge;100 per 100,000 population) (<a href=\"image.htm?imageKey=ID%2F111123\" class=\"graphic graphic_table graphicRef111123 \">table 1</a>), reduction in risk of TB disease increases with duration of LTBI treatment, and the benefit of therapy wanes after treatment discontinuation [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/7,18\" class=\"abstract_t\">7,18</a>]. We are in agreement with the World Health Organization 2018 guidelines, which recommend <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> monotherapy for at least 36 months in all HIV-infected patients with a positive TST or unknown TST status in whom active TB is excluded; this includes individuals on antiretroviral therapy [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/2\" class=\"abstract_t\">2</a>]. However, extended isoniazid therapy (ie, beyond 12 months) is associated with increased patient burden and cost and may be associated with increased toxicity and diminished adherence [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/4,18,41\" class=\"abstract_t\">4,18,41</a>].</p><p>The above approach is supported by a systematic review and meta-analysis including more than 3000 HIV-infected individuals in settings with high TB incidence, in which continuous <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> preventive therapy was 38 percent more effective in reducing the risk of active TB than a six-month course of isoniazid; the effect was greater in individuals with a positive TST [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/7,18,54,55\" class=\"abstract_t\">7,18,54,55</a>].</p><p>Empiric initiation of treatment for active TB disease (four-drug therapy) is not superior to preventive therapy (single-drug therapy) for reduction of mortality. In one study including 850 patients with advanced HIV starting antiretroviral therapy in 10 low- or middle-income countries, there was no difference in mortality associated with empiric initiation of treatment for active TB disease compared with preventive therapy. All study participants underwent intensive screening to exclude active disease including locally available diagnostics such as chest radiographs and sputum examination with GeneXpert [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/56\" class=\"abstract_t\">56</a>].</p><p>The optimal approach to LTBI treatment in settings with extremely high transmission, such as the South African gold mines (where close quarters and frequent HIV coinfection produce some of the highest tuberculosis rates in the world) is uncertain. One trial noted that mass screening and treatment for latent tuberculosis had no significant effect on tuberculosis control in this setting, despite success of <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> in preventing tuberculosis during LTBI treatment [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/57\" class=\"abstract_t\">57</a>].</p><p class=\"headingAnchor\" id=\"H7712614\"><span class=\"h3\">Patient monitoring</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients should be counseled on the symptoms and signs of drug-induced hepatitis (eg, right upper quadrant pain, jaundice, nausea, vomiting, loss of appetite, dark urine) and instructed to report these promptly. Patients should be monitored monthly for signs and symptoms of adverse drug events and development of active TB [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/37\" class=\"abstract_t\">37</a>]; regular patient-doctor interactions also provide an opportunity to reinforce the importance of drug adherence.</p><p>The risk of drug-induced hepatotoxicity associated with <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> increases with age [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/58\" class=\"abstract_t\">58</a>] and alcohol use [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/58\" class=\"abstract_t\">58</a>]. There is no consistent evidence of increased toxicity of LTBI therapy in HIV-infected individuals [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/59,60\" class=\"abstract_t\">59,60</a>]. In fact, one trial of combination therapy with <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> and <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a> noted the incidence of drug-induced liver injury was lower among the patients with HIV infection than those without HIV infection [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/59,60\" class=\"abstract_t\">59,60</a>]. (See <a href=\"topic.htm?path=treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy#H2848278702\" class=\"medical medical_review\">&quot;Treatment of pulmonary tuberculosis in HIV-infected adults: Follow-up after initiation of therapy&quot;, section on 'Drug-related side effects'</a>.)</p><p>There is no consensus on the need for or benefits of routine aminotransferase monitoring in patients taking treatment for LTBI. Patients with abnormal baseline aminotransferases (obtained in patients with known or suspected liver disease) should undergo routine monitoring; the optimal frequency of monitoring is unknown [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/25,37\" class=\"abstract_t\">25,37</a>].</p><p>On the basis of clinical experience in the absence of published data, it is reasonable that HIV-infected individuals with no other risk factors for hepatotoxicity have monitoring as practiced for HIV-uninfected individuals. (See <a href=\"topic.htm?path=treatment-of-latent-tuberculosis-infection-in-hiv-uninfected-adults#H9\" class=\"medical medical_review\">&quot;Treatment of latent tuberculosis infection in HIV-uninfected adults&quot;, section on 'Monitoring'</a>.)</p><p>A single aminotransferase assay after approximately one month of therapy is reasonable; otherwise, laboratory monitoring is warranted only in the setting of clinical symptoms or other concern for hepatoxicity. Patients with additional risk factors for hepatotoxicity (eg, preexisting liver disease) should have assays of aminotransferases every month during treatment. (See <a href=\"#H7704620\" class=\"local\">'Baseline laboratory testing'</a> above.)</p><p class=\"headingAnchor\" id=\"H7711851\"><span class=\"h4\">Drug toxicity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Adverse events and drug discontinuation rates are generally lower among patients taking monotherapy compared with combination therapy and among those taking short-term <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> compared with long-term isoniazid [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/7,8,21\" class=\"abstract_t\">7,8,21</a>].</p><p class=\"headingAnchor\" id=\"H7711924\"><span class=\"h5\">Isoniazid</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The major toxicities associated with <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> include peripheral neuropathy and hepatotoxicity. HIV-infected patients who receive isoniazid should also receive supplemental <a href=\"topic.htm?path=vitamin-b6-pyridoxine-drug-information\" class=\"drug drug_general\">vitamin B6</a> to prevent peripheral neuropathy.</p><p>Peripheral neuropathy has also been associated with the HIV nucleoside analog <a href=\"topic.htm?path=stavudine-drug-information\" class=\"drug drug_general\">stavudine</a>, which is no longer recommended for HIV therapy, including in resource-limited settings. Patients taking <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> should not take concomitant stavudine.</p><p>Drug-induced liver injury has been associated with <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/36\" class=\"abstract_t\">36</a>] as well as certain antiretroviral medications [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/61\" class=\"abstract_t\">61</a>]. Patients should also be educated regarding the signs and symptoms of hepatitis. (See <a href=\"#H7712614\" class=\"local\">'Patient monitoring'</a> above.)</p><p class=\"headingAnchor\" id=\"H7711985\"><span class=\"h5\">Rifamycins</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Both <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> and <a href=\"topic.htm?path=rifapentine-drug-information\" class=\"drug drug_general\">rifapentine</a> have been evaluated for prevention of TB in HIV-infected and HIV-uninfected patients, usually given in combination with <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/18,21,62,63\" class=\"abstract_t\">18,21,62,63</a>]. Rifapentine has similar antituberculous potency as rifampin, but its half-life is five times longer, allowing once-weekly administration.</p><p>In HIV-uninfected patients, monotherapy with rifamycins is associated with a lower risk of hepatotoxicity than <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/21,62-65\" class=\"abstract_t\">21,62-65</a>]. However, clinical trials of LTBI treatment in HIV-infected patients have used rifamycins in combination with other agents (eg, isoniazid), so the individual toxicity profile of rifamycins in this patient population is uncertain. (See <a href=\"topic.htm?path=rifamycins-rifampin-rifabutin-rifapentine#H9\" class=\"medical medical_review\">&quot;Rifamycins (rifampin, rifabutin, rifapentine)&quot;, section on 'Adverse effects'</a>.)</p><p>The major concern regarding the use of rifamycins in HIV-infected patients is related to potential drug-drug interactions with antiretroviral medications. Rifamycins induce hepatic CYP3A4 enzymes that can accelerate metabolism of HIV protease inhibitors (PIs) and some nonnucleoside reverse transcriptase inhibitors (NNRTIs) [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/52,66\" class=\"abstract_t\">52,66</a>]. (See <a href=\"topic.htm?path=rifamycins-rifampin-rifabutin-rifapentine#H9\" class=\"medical medical_review\">&quot;Rifamycins (rifampin, rifabutin, rifapentine)&quot;, section on 'Adverse effects'</a>.)</p><p>There are no data on the use of <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a> monotherapy for LTBI in HIV-infected patients.</p><p><a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">Rifampin</a> plus <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a> should not be used for treatment of LTBI due to hepatotoxicity [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/44,53\" class=\"abstract_t\">44,53</a>].</p><p class=\"headingAnchor\" id=\"H7709761\"><span class=\"h3\">Special circumstances</span></p><p class=\"headingAnchor\" id=\"H7709713\"><span class=\"h4\">Drug-resistant infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Issues related to LTBI among HIV-infected patients with possible drug-resistant TB are discussed separately. (See <a href=\"topic.htm?path=treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults\" class=\"medical medical_review\">&quot;Treatment of drug-resistant pulmonary tuberculosis in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H7709731\"><span class=\"h4\">Pregnancy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Issues related to LTBI during pregnancy among HIV-infected patients are discussed separately. (See <a href=\"topic.htm?path=tuberculosis-in-pregnancy#H4\" class=\"medical medical_review\">&quot;Tuberculosis in pregnancy&quot;, section on 'Treatment'</a>.)</p><p class=\"headingAnchor\" id=\"H1417217608\"><span class=\"h2\">Initiation of antiretroviral therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Early initiation of ART has been associated with lower incidence of active tuberculosis among HIV-infected patients in TB-endemic areas [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/6,7,30,67-70\" class=\"abstract_t\">6,7,30,67-70</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a randomized trial including more than 2000 HIV-infected patients in the Ivory Coast with CD4 &lt;800 <span class=\"nowrap\">cells/mm<sup>3</sup>,</span> both ART and six months of <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> preventive therapy were independently associated with lower rates of active tuberculosis [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/30\" class=\"abstract_t\">30</a>]. There was a significant benefit of early ART even among participants with CD4 of 500 to 800 <span class=\"nowrap\">cells/mm<sup>3</sup></span> at enrollment. (See <a href=\"topic.htm?path=the-impact-of-antiretroviral-therapy-on-morbidity-and-mortality-of-hiv-infection-in-resource-limited-settings#H12409076\" class=\"medical medical_review\">&quot;The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-limited settings&quot;, section on 'Tuberculosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a randomized trial including more than 4600 HIV-infected patients around the world with CD4 counts &gt;500 <span class=\"nowrap\">cells/mm<sup>3</sup>,</span> active TB developed less frequently among those who received immediate ART than among those who started ART only when their CD4 count dropped to 350 <span class=\"nowrap\">cells/mm<sup>3</sup></span> or when they developed a clinical condition that required ART (14 versus 20 percent) [<a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/71\" class=\"abstract_t\">71</a>].</p><p/><p class=\"headingAnchor\" id=\"H975574247\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-diagnosis-and-treatment-of-tuberculosis\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Diagnosis and treatment of tuberculosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1862358\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Individuals with latent tuberculosis infection (LTBI) are asymptomatic and not infectious. Latent tuberculosis (TB) bacilli remain viable and may reactivate years later, causing active symptomatic and transmissible TB disease. HIV-infected patients with LTBI are significantly more likely to reactivate with TB disease than HIV-uninfected individuals. (See <a href=\"#H8400290\" class=\"local\">'General concepts'</a> above and <a href=\"#H670608\" class=\"local\">'Risk factors for progression'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment of latent TB is associated with two important benefits: (1) reduction in the likelihood of progression to active TB disease, and (2) reduction in TB transmission. (See <a href=\"#H8400317\" class=\"local\">'Rationale for LTBI treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>LTBI treatment is warranted for HIV-infected patients in the following circumstances (see <a href=\"#H7701804\" class=\"local\">'Whom to treat'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Individuals with recent contact with a person with active TB disease</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Individuals with a history of inadequately treated healed TB (eg, fibrotic disease on chest radiograph), regardless of test results for LTBI (see <a href=\"#H670608\" class=\"local\">'Risk factors for progression'</a> above)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Individuals with evidence of LTBI by <a href=\"topic.htm?path=tuberculin-skin-test-drug-information\" class=\"drug drug_general\">tuberculin skin test</a> (TST) or interferon-gamma release assay (IGRA)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Individuals living in resource-limited areas of high TB incidence where testing for LTBI is not available </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prior to the initiation of treatment for LTBI, all patients must be evaluated for active TB infection to avoid monotherapy and the risk of TB drug resistance. (See <a href=\"#H7704536\" class=\"local\">'Assessment for TB disease'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Routine baseline laboratory testing is not required prior to the initiation of treatment of LTBI. Baseline testing of aminotransferases is warranted for individuals with a history of liver disease (eg, alcoholic, viral hepatitis). (See <a href=\"#H7704620\" class=\"local\">'Baseline laboratory testing'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">Isoniazid</a> is preferred for the treatment of LTBI in HIV-infected patients because of its overall efficacy, safety, and cost. The optimal duration of therapy for LTBI is unknown. In resource-rich settings, most patients are treated with nine months of daily isoniazid (300 mg daily). (See <a href=\"#H7701972\" class=\"local\">'Low-incidence settings'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In high-incidence settings (incidence rate &ge;100 per 100,000 population), reduction in risk of TB disease increases with duration of LTBI treatment, and the benefit of therapy wanes after treatment discontinuation. In these settings, the World Health Organization (WHO) guidelines recommend <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a> monotherapy for a minimum of six months in HIV-infected patients. In the 2018 guidelines, the WHO has recommended the 36-month regimen be offered to HIV-infected persons in setting with high TB incidence and transmission. It should be noted, however, that the identification of such settings (ie, &quot;what is high incidence and transmission?&quot;) is left to national authorities to define. (See <a href=\"#H3662714639\" class=\"local\">'High-incidence settings'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>All patients should be counseled on the symptoms and signs of drug-induced hepatitis (eg, right upper quadrant pain, jaundice, nausea, vomiting, loss of appetite, dark urine). There is no consensus on the need for or benefits of routine monitoring of aminotransferases in patients taking treatment for LTBI. (See <a href=\"#H7712614\" class=\"local\">'Patient monitoring'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Early initiation of antiretroviral therapy (ie, for CD4 &lt;800 <span class=\"nowrap\">cells/mm<sup>3</sup>)</span> has been associated with lower incidence of active tuberculosis among HIV-infected patients in TB-endemic areas. (See <a href=\"#H1417217608\" class=\"local\">'Initiation of antiretroviral therapy'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li class=\"breakAll\">Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf (Accessed on July 10, 2017).</li><li class=\"breakAll\">World Health Organization. Latent TB Infection: Updated and consolidated guidelines for programmatic management, 2018. http://www.who.int/tb/publications/2018/latent-tuberculosis-infection/en/ (Accessed on March 06, 2018).</li><li class=\"breakAll\">World Health Organization. Global Tuberculosis Control. Surveillance, Planning, Financing: 2010. World Health Organization, Geneva 2011 (WHO/HTM/TB/2010.362).</li><li class=\"breakAll\">World Health Organization. Guidelines for Intensified tuberculosis case finding and isoniazid preventive therapy for people living with HIV in resource constrained settings, Geneva, 2011.</li><li class=\"breakAll\">CDC. Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC. MMWR 2005;54(No. RR-15).</li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/6\" class=\"nounderline abstract_t\">Elzi L, Schlegel M, Weber R, et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis 2007; 44:94.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/7\" class=\"nounderline abstract_t\">Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377:1588.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/8\" class=\"nounderline abstract_t\">Mwinga A, Hosp M, Godfrey-Faussett P, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998; 12:2447.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/9\" class=\"nounderline abstract_t\">Sterling TR, Lau B, Zhang J, et al. Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. J Infect Dis 2011; 204:893.</a></li><li class=\"breakAll\">Shwander SK, Ellner J. The human host: Immunology and susceptibility. In: Tuberculosis, 20th ed, Raviglione MC (Ed), Informa Healthcare, New York 2006. p.117.</li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/11\" class=\"nounderline abstract_t\">Menzies D, Fanning A, Yuan L, Fitzgerald M. Tuberculosis among health care workers. N Engl J Med 1995; 332:92.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/12\" class=\"nounderline abstract_t\">Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992; 326:231.</a></li><li class=\"breakAll\">Page KR, Godfrey-Fausset P, Chaisson RE. Tuberculosis-HIV coinfection: epidemiology, clinical aspects, and interventions. In: Reichman and Hershfield's Tuberculosis: A Comprehensive International Approach, Raviglione MC (Ed), Informa Healthcare, New York 2006. p.371.</li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/14\" class=\"nounderline abstract_t\">Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/15\" class=\"nounderline abstract_t\">Wood R, Maartens G, Lombard CJ. Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr 2000; 23:75.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/16\" class=\"nounderline abstract_t\">Comstock GW, Edwards LB, Livesay VT. Tuberculosis morbidity in the U.S. Navy: its distribution and decline. Am Rev Respir Dis 1974; 110:572.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/17\" class=\"nounderline abstract_t\">Golub JE, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 2009; 23:631.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/18\" class=\"nounderline abstract_t\">Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011; 365:11.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/19\" class=\"nounderline abstract_t\">Jordan TJ, Lewit EM, Montgomery RL, Reichman LB. Isoniazid as preventive therapy in HIV-infected intravenous drug abusers. A decision analysis. JAMA 1991; 265:2987.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/20\" class=\"nounderline abstract_t\">Sterling TR, Bethel J, Goldberg S, et al. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med 2006; 173:927.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/21\" class=\"nounderline abstract_t\">Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010; :CD000171.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/22\" class=\"nounderline abstract_t\">Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997; 337:801.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/23\" class=\"nounderline abstract_t\">Cohen T, Lipsitch M, Walensky RP, Murray M. Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proc Natl Acad Sci U S A 2006; 103:7042.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/24\" class=\"nounderline abstract_t\">Foster S, Godfrey-Faussett P, Porter J. Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia. AIDS 1997; 11:919.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/25\" class=\"nounderline abstract_t\">Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000; 161:S221.</a></li><li class=\"breakAll\">Tuberculosis Prevention and Control, Public Health Agency of Canada, the Canadian Lung Association. Canadian Lung Association, 6th ed, Long RL, Ellis E (Eds), Public Health Agency of Canada, Toronto 2007.</li><li class=\"breakAll\">World Health Organization. WHO Three I's Meeting, World Health Organization, Geneva, 2009. p.161.</li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/28\" class=\"nounderline abstract_t\">Harries AD, Zachariah R, Corbett EL, et al. The HIV-associated tuberculosis epidemic--when will we act? Lancet 2010; 375:1906.</a></li><li class=\"breakAll\">http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5302a6.htm (Accessed on August 29, 2011).</li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/30\" class=\"nounderline abstract_t\">TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med 2015; 373:808.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/31\" class=\"nounderline abstract_t\">Golub JE, Cohn S, Saraceni V, et al. Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study. Clin Infect Dis 2015; 60:639.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/32\" class=\"nounderline abstract_t\">Rangaka MX, Wilkinson RJ, Boulle A, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet 2014; 384:682.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/33\" class=\"nounderline abstract_t\">Mtei L, Matee M, Herfort O, et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis 2005; 40:1500.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/34\" class=\"nounderline abstract_t\">Day JH, Charalambous S, Fielding KL, et al. Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South Africa. Int J Tuberc Lung Dis 2006; 10:523.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/35\" class=\"nounderline abstract_t\">Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 2015; 46:1563.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/36\" class=\"nounderline abstract_t\">Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174:935.</a></li><li class=\"breakAll\">AIDSinfo. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Mycobacterium tuberculosis infection and disease. https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/325/tb (Accessed on July 13, 2017).</li><li class=\"breakAll\">Centers for Disease Control and Prevention. Treatment Regimens for Latent TB Infection (LTBI). http://www.cdc.gov/tb/topic/treatment/ltbi.htm (Accessed on September 26, 2016).</li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/39\" class=\"nounderline abstract_t\">Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000; :CD001363.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/40\" class=\"nounderline abstract_t\">Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ 1982; 60:555.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/41\" class=\"nounderline abstract_t\">Snider DE Jr, Caras GJ, Koplan JP. Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy. JAMA 1986; 255:1579.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/42\" class=\"nounderline abstract_t\">Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999; 3:847.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/43\" class=\"nounderline abstract_t\">Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 1970; 26:28.</a></li><li class=\"breakAll\">AIDS Info: Clinical Guidelines Portal. http://aidsinfo.nih.gov/guidelines (Accessed on May 14, 2015).</li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/45\" class=\"nounderline abstract_t\">Sterling TR, Scott NA, Miro JM, et al. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS 2016; 30:1607.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/46\" class=\"nounderline abstract_t\">Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365:2155.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/47\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep 2011; 60:1650.</a></li><li class=\"breakAll\">Farenc C, Doroumian S, Cantalloube C, et al. Rifapentine Once-Weekly Dosing Effect on Efavirenz Emtricitabine and Tenofovir PKs. 21st Conference on Retroviruses and Opportunistic Infections, Boston, MA 2014.</li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/49\" class=\"nounderline abstract_t\">Weiner M, Egelund EF, Engle M, et al. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother 2014; 69:1079.</a></li><li class=\"breakAll\">Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf (Accessed on September 26, 2016).</li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/51\" class=\"nounderline abstract_t\">Brooks KM, George JM, Pau AK, et al. Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir with Once-Weekly Isoniazid and Rifapentine. Clin Infect Dis 2018.</a></li><li class=\"breakAll\">Centers for Disease Control and Prevention. Managing drug interactions in the treatment of HIV-related tuberculosis. 2013. http://www.cdc.gov/tb/publications/guidelines/TB_HIV_Drugs/default.htm (Accessed on April 20, 2015).</li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/53\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC), American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:735.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/54\" class=\"nounderline abstract_t\">Den Boon S, Matteelli A, Ford N, Getahun H. Continuous isoniazid for the treatment of latent tuberculosis infection in people living with HIV. AIDS 2016; 30:797.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/55\" class=\"nounderline abstract_t\">Swaminathan S, Menon PA, Gopalan N, et al. Efficacy of a six-month versus a 36-month regimen for prevention of tuberculosis in HIV-infected persons in India: a randomized clinical trial. PLoS One 2012; 7:e47400.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/56\" class=\"nounderline abstract_t\">Hosseinipour MC, Bisson GP, Miyahara S, et al. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. Lancet 2016; 387:1198.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/57\" class=\"nounderline abstract_t\">Churchyard GJ, Fielding KL, Lewis JJ, et al. A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med 2014; 370:301.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/58\" class=\"nounderline abstract_t\">Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978; 117:991.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/59\" class=\"nounderline abstract_t\">Gordin F, Chaisson RE, Matts JP, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA 2000; 283:1445.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/60\" class=\"nounderline abstract_t\">Gao XF, Wang L, Liu GJ, et al. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis. Int J Tuberc Lung Dis 2006; 10:1080.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/61\" class=\"nounderline abstract_t\">Soriano V, Puoti M, Garcia-Gasc&oacute; P, et al. Antiretroviral drugs and liver injury. AIDS 2008; 22:1.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/62\" class=\"nounderline abstract_t\">A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis 1992; 145:36.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/63\" class=\"nounderline abstract_t\">Villarino ME, Ridzon R, Weismuller PC, et al. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am J Respir Crit Care Med 1997; 155:1735.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/64\" class=\"nounderline abstract_t\">Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008; 149:689.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/65\" class=\"nounderline abstract_t\">Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991; 99:465.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/66\" class=\"nounderline abstract_t\">Burger DM, Agarwala S, Child M, et al. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicrob Agents Chemother 2006; 50:3336.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/67\" class=\"nounderline abstract_t\">Severe P, Pape J, Fitzgerald D. A randomized clinical trial of early versus standard antiretroviral therapy for HIV-infected patients with a CD4 T-cell count of 200-350 cells/mL (CIPRAHT001). Paper presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 12-15, 2009; San Francisco, CA. Abstract:H1230c.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/68\" class=\"nounderline abstract_t\">Lawn SD, Myer L, Edwards D, et al. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009; 23:1717.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/69\" class=\"nounderline abstract_t\">Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/70\" class=\"nounderline abstract_t\">Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010; 363:257.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-latent-tuberculosis-infection-in-hiv-infected-adults/abstract/71\" class=\"nounderline abstract_t\">INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med 2015; 373:795.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 8011 Version 38.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H1862358\"><span>SUMMARY</span></a></li><li><a href=\"#H107991584\" id=\"outline-link-H107991584\">INTRODUCTION</a></li><li><a href=\"#H8400290\" id=\"outline-link-H8400290\">GENERAL CONCEPTS</a><ul><li><a href=\"#H670608\" id=\"outline-link-H670608\">Risk factors for progression</a></li><li><a href=\"#H8400317\" id=\"outline-link-H8400317\">Rationale for LTBI treatment</a></li></ul></li><li><a href=\"#H7701782\" id=\"outline-link-H7701782\">CLINICAL APPROACH</a><ul><li><a href=\"#H291024591\" id=\"outline-link-H291024591\">Treatment of LTBI</a><ul><li><a href=\"#H7701804\" id=\"outline-link-H7701804\">- Whom to treat</a></li><li><a href=\"#H7704706\" id=\"outline-link-H7704706\">- Prior to treatment</a><ul><li><a href=\"#H7704536\" id=\"outline-link-H7704536\">Assessment for TB disease</a></li><li><a href=\"#H7704620\" id=\"outline-link-H7704620\">Baseline laboratory testing</a></li></ul></li><li><a href=\"#H7701941\" id=\"outline-link-H7701941\">- Treatment regimens</a><ul><li><a href=\"#H7701972\" id=\"outline-link-H7701972\">Low-incidence settings</a></li><li><a href=\"#H3662714639\" id=\"outline-link-H3662714639\">High-incidence settings</a></li></ul></li><li><a href=\"#H7712614\" id=\"outline-link-H7712614\">- Patient monitoring</a><ul><li><a href=\"#H7711851\" id=\"outline-link-H7711851\">Drug toxicity</a><ul><li><a href=\"#H7711924\" id=\"outline-link-H7711924\">- Isoniazid</a></li><li><a href=\"#H7711985\" id=\"outline-link-H7711985\">- Rifamycins</a></li></ul></li></ul></li><li><a href=\"#H7709761\" id=\"outline-link-H7709761\">- Special circumstances</a><ul><li><a href=\"#H7709713\" id=\"outline-link-H7709713\">Drug-resistant infection</a></li><li><a href=\"#H7709731\" id=\"outline-link-H7709731\">Pregnancy</a></li></ul></li></ul></li><li><a href=\"#H1417217608\" id=\"outline-link-H1417217608\">Initiation of antiretroviral therapy</a></li></ul></li><li><a href=\"#H975574247\" id=\"outline-link-H975574247\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H1862358\" id=\"outline-link-H1862358\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/8011|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/111123\" class=\"graphic graphic_table\">- Countries with tuberculosis incidence &gt;100 per 100,000</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-diagnosis-of-latent-tuberculosis-infection-tuberculosis-screening-in-adults\" class=\"medical medical_review\">Approach to diagnosis of latent tuberculosis infection (tuberculosis screening) in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-pulmonary-tuberculosis-in-adults\" class=\"medical medical_review\">Diagnosis of pulmonary tuberculosis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=isoniazid-an-overview\" class=\"medical medical_review\">Isoniazid: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rifamycins-rifampin-rifabutin-rifapentine\" class=\"medical medical_review\">Rifamycins (rifampin, rifabutin, rifapentine)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-diagnosis-and-treatment-of-tuberculosis\" class=\"medical medical_society_guidelines\">Society guideline links: Diagnosis and treatment of tuberculosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-impact-of-antiretroviral-therapy-on-morbidity-and-mortality-of-hiv-infection-in-resource-limited-settings\" class=\"medical medical_review\">The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-limited settings</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults\" class=\"medical medical_review\">Treatment of drug-resistant pulmonary tuberculosis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-latent-tuberculosis-infection-in-hiv-uninfected-adults\" class=\"medical medical_review\">Treatment of latent tuberculosis infection in HIV-uninfected adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy\" class=\"medical medical_review\">Treatment of pulmonary tuberculosis in HIV-infected adults: Follow-up after initiation of therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy\" class=\"medical medical_review\">Treatment of pulmonary tuberculosis in HIV-infected adults: Initiation of therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tuberculosis-in-pregnancy\" class=\"medical medical_review\">Tuberculosis in pregnancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tuberculosis-natural-history-microbiology-and-pathogenesis\" class=\"medical medical_review\">Tuberculosis: Natural history, microbiology, and pathogenesis</a></li></ul></div></div>","javascript":null}